6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Dexamethasone Inhibits Corticotropin-Releasing Factor Gene Expression in the Rat Paraventricular Nucleus

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of glucocorticoids on corticotropin-releasing factor (CRF) gene expression was studied by combination of in situ hybridization histochemistry and steroid implantation. Dexamethasone micropellets, implanted around the hypothalamic paraventricular nucleus (PVN), caused total inhibition of the hybridizable CRF mRNA signal above the parvocellular neurons of the PVN. Unilateral implantation of dexamethasone around the PVN resulted in a decrease of hybridizable CRF mRNA at the dexamethasone-implanted side. Dexamethasone implants into the cerebral cortex, dorsal hippocampus, ventral subiculum, lateral septum or amygdala were without any effect on the CRF expression in the PVN. Corticosterone did not result in any significant change in CRF mRNA, when implanted into the paraventricular region, dorsal hippocampus or ventral subiculum. When it was placed into the amygdala however, in a few cases it slightly inhibited the CRF mRNA levels in the ipsilateral PVN.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1987
          1987
          02 April 2008
          : 46
          : 4
          : 365-368
          Affiliations
          aInstitute of Experimental Medicine, Hungarian Academy of Science, and bFirst Department of Anatomy, Semmelweis University Medical School, Budapest, Hungary
          Article
          124846 Neuroendocrinology 1987;46:365–368
          10.1159/000124846
          3499580
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Rapid Communication

          Comments

          Comment on this article